The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).

Start Date01 Jun 2016

Sponsor / Collaborator

Eli Lilly & Co.

NCT02614131 / TerminatedPhase 1

Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's Disease (AD), and those with mild-to-moderate AD. The study will measure how much LY2599666 gets into the bloodstream and how long it takes the body to get rid of it. It will also evaluate how LY2599666 affects the body. The study has three parts. Part A will last about 2 months. Parts B and C will each last about 23 weeks. Participants may only enroll in one part.

Start Date01 Dec 2015

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Solanezumab

100 Translational Medicine associated with Solanezumab

100 Patents (Medical) associated with Solanezumab

594

Literatures (Medical) associated with Solanezumab

01 Dec 2024·Phytomedicine

Osmundacetone ameliorates Alzheimer's-like pathologies by inhibiting β-amyloid fibrillation, oxidative damage and neuroinflammation in APP/PS1 transgenic mice

Article

Author: Fan, Yong-Gang ; Wang, Zhan-You ; Wu, Ting-Yao ; Zhao, Ling-Xiao ; Ren, Hang ; Zhang, Yan-Hui ; Su, Jing-Yang ; Zhang, Qi ; He, Da-Long

BACKGROUNDβ-Amyloid (Aβ) fibrillation is critical for Aβ deposition and cytotoxicity during the progression of Alzheimer's disease (AD). Consequently, anti-Aβ monoclonal antibody drugs targeting Aβ oligomers and aggregation are considered potential therapeutic strategies for AD treatment. Similar to the working mechanisms of anti-Aβ monoclonal antibody drugs, our study identified osmundacetone (OAC), a small-molecule compound isolated from the traditional Chinese medicine Rhizoma Osmundae, as exerting anti-AD effects by targeting Aβ.PURPOSEThis study sought to determine whether OAC influences the Aβ burden in APP/PS1 mice and to identify potential regulatory mechanisms.METHODSFive-month-old APP/PS1 mice were injected intraperitoneally with OAC at a dose of 1 mg/kg for 12 weeks. The cognitive functions of the mice were assessed via the Morris water maze test and the open field test. Osmundacetone was analyzed via molecular docking, an isothermal dose‒response fingerprint-cellular context thermal shift assay, a thioflavine T fluorescence assay, and an atomic force microscopy assay to analyze the effects of OAC on Aβ fibrillation. Immunofluorescence, immunoblotting, and immunohistochemistry were used to assess Aβ clearance, AD pathology, oxidative stress, and inflammatory responses.RESULTSThe innovative biochemical and physical data illustrated that the ability of OAC to inhibit Aβ fibrillation was accomplished by binding directly to Aβ, which differed from the majority of previously reported natural polyphenols that modulate the Aβ content and structure in an indirect manner. The inhibition of Aβ fibrosis by OAC subsequently promoted Aβ lysosomal degradation, resulting in a decreased Aβ burden in APP/PS1 mice. Furthermore, OAC treatment inhibited oxidative damage by upregulating glutathione peroxidase expression and attenuated the production of inflammatory factors by downregulating nuclear factor-kB phosphorylation in APP/PS1 mice.CONCLUSIONThese findings demonstrate, for the first time, that OAC could reduce the brain Aβ burden in APP/PS1 mice by inhibiting Aβ fibrillation through direct binding to Aβ and improve cognitive dysfunction by attenuating oxidative damage and neuroinflammation. These findings indicate that OAC may be a promising candidate for the treatment of AD.

18 Oct 2024·Journal of Alzheimer's Disease

BACE Inhibitor Clinical Trials for Alzheimer’s Disease

Review

Author: Vassar, Robert ; Perry, George ; Plascencia-Villa, German ; Moreira, Paula I. ; Zhu, Xiongwei ; Avila, Jesus ; Galimberti, Daniela ; Pappolla, Miguel A. ; Sorensen, Aaron A. ; Watkins, Elyse A.

The amyloid hypothesis posits that the amyloid-β aggregates in the brain initiate a cascade of events that eventually lead to neuron loss and Alzheimer’s disease. Recent clinical trials of passive immunotherapy with anti-amyloid-β antibodies support this hypothesis, because clearing plaques led to better cognitive outcomes. Orally available small molecule BACE1 inhibitors are another approach to slowing the buildup of plaques and thereby cognitive worsening by preventing the cleavage of amyloid-β protein precursor (AβPP) into amyloid-β peptide, the major component of plaques. This approach is particularly attractive because of their ease of use, low cost, and advanced clinical stage. However, although effective in preventing amyloid-β production in late-stage clinical trials, BACE inhibitors have been associated with early, non-progressive, likely reversible, cognitive decline. The clinical trials tested high levels of BACE inhibition, greater than 50%, whereas genetics suggest that even a 30% inhibition may be sufficient to protect from Alzheimer’s disease. Aside from AβPP, BACE1 cleaves many other substrates in the brain that may be contributing to the cognitive worsening. It is important to know what the cause of cognitive worsening is, and if a lower level of inhibition would sufficiently slow the progress of pathology while preventing these unwanted side effects. Should these side effects be mitigated, BACE inhibitors could rapidly move forward in clinical trials either as a primary prevention strategy in individuals that are at risk or biomarker positive, or as a maintenance therapy following amyloid clearance with an anti-amyloid antibody.

03 Oct 2024·Brain

Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials

Article

Author: Espay, Alberto J ; Abanto, Jesus ; Imbimbo, Bruno P ; Dwivedi, Alok K

AbstractPositive effects of new anti-amyloid-β (Aβ) monoclonal antibodies in Alzheimer’s disease (AD) have been attributed to brain amyloid reduction. However, most anti-Aβ antibodies also increase the CSF levels of the 42-amino acid isoform (Aβ42). We evaluated the associations of changes in CSF Aβ42 and brain Aβ-PET with cognitive and clinical end points in randomized trials of anti-Aβ drugs that lowered (β- and γ-secretase inhibitors) or increased CSF Aβ42 levels (anti-Aβ monoclonal antibodies) to test the hypothesis that post-treatment increases in CSF Aβ42 levels are independently associated with cognitive and clinical outcomes.From long-term (≥12 months) randomized placebo-controlled clinical trials of anti-Aβ drugs published until November 2023, we calculated the post-treatment versus baseline difference in ADAS-Cog (cognitive subscale of the Alzheimer’s Disease Assessment Scale) and CDR-SB (Clinical Dementia Rate-Sum of Boxes) and z-standardized changes in CSF Aβ42 and Aβ-PET Centiloids (CL). We estimated the effect size [regression coefficients (RCs) and confidence intervals (CIs)] and the heterogeneity (I2) of the associations between AD biomarkers and cognitive and clinical end points using random-effects meta-regression models.We included 25 966 subjects with AD from 24 trials. In random-effects analysis, increases in CSF Aβ42 were associated with slower decline in ADAS-Cog (RC: −0.55; 95% CI: −0.89, −0.21, P = 0.003, I2 = 61.4%) and CDR-SB (RC: −0.16; 95% CI: −0.26, −0.06, P = 0.002, I2 = 34.5%). Similarly, decreases in Aβ–PET were associated with slower decline in ADAS-Cog (RC: 0.69; 95% CI: 0.48, 0.89, P < 0.001, I2 = 0%) and CDR-SB (RC: 0.26; 95% CI: 0.18, 0.33, P < 0.001, I2 = 0%). Sensitivity analyses yielded similar results.Higher CSF Aβ42 levels after exposure to anti-Aβ drugs are independently associated with slowing cognitive impairment and clinical decline. Increases in Aβ42 may represent a mechanism of potential benefit of anti-Aβ monoclonal antibodies in AD.

News (Medical) associated with Solanezumab

10 Jun 2024

·www.biopharmadive.com

Lilly Alzheimer’s drug gets unanimous backing of FDA panel

An experimental and closely watched medicine for Alzheimers disease is one step closer to approval, after receiving support from a panel of experts who advise the Food and Drug Administration.On Monday, the panel unanimously voted that the medicine, developed by Eli Lilly and known as donanemab, appears to be an effective treatment for certain Alzheimers patients. The experts also concluded, by an 11-0 vote, that the drugs benefits outweigh its risks, despite some safety concerns.I thought the evidence is very strong and the trials [show] the effectiveness of the drug, said Dean Follman, a panelist and assistant director of biostatistics at the National Institute of Allergy and Infectious Diseases.Though the FDA isnt required to follow the recommendations of its advisory committees, it typically does. Should the agency grant approval, donanemab would be the third Alzheimers therapy of its kind cleared for the U.S. market. These medicines work by breaking up sticky, toxic collections of amyloid beta, a protein many researchers believe to be a root cause of the memory-robbing disease.Whether Lillys drug can avoid the obstacles that have held back its predecessors remains unclear. The first product in this class, Biogen and Eisais Aduhelm, was mired in controversy and eventually withdrawn from market. A second, newer option from those companies called Leqembi is faring better commercially. But both Biogen and Eisai acknowledge Leqembis launch has been more challenging than they anticipated.Lilly built its approval application around a placebo-controlled clinical trial that enrolled nearly 1,700 people in early stages of Alzheimers disease. The trial found participants who were given donanemab declined 22% slower than those who were in the control group, as measured by a rating scale that combines two well-known scoring systems for evaluating the severity of Alzheimers symptoms.FDA advisers acknowledged the positive results, yet questioned how applicable they would be to the broader Alzheimers population. All study participants were in earlier stages of the disease, and most were white.Additionally, Lillys study had unique design elements that made evaluating the results trickier. For example, in order to enroll, participants had to test positive not only for amyloid, but also for another protein tied to the development of Alzheimers. The trial found the disease progressed even slower among donanemab-treated patients with low to medium levels of this tau protein.FDA advisers therefore wanted more clarity about the role tau would play in prescribing the drug if it were approved especially since testing for tau requires PET scans, which can be costly and time-consuming.Inclusion of requirements for [tau testing] will further limit the number of patients who can have access to these types of medications, said Cynthia Carlsson, a panelist and a professor of medicine at the University of Wisconsin School of Medicine and Public Health.So it's a nuanced situation where, on the one hand, we do need to have additional data on the no and very low tau population. And on the other hand, we should not require having [tau testing] for access to this medication.Teresa Burrachio, the director of FDAs neuroscience office, noted early on in the meeting that tau burden wouldnt necessarily affect the agencys approval decision, but could potentially be a consideration for labeling.Another distinctive choice Lilly made in running its study was to have participants discontinue donanemab if amyloid levels dropped below a certain threshold. While some panelists described this design as innovative, they still questioned how it would translate to real-world treatment. What would happen, they asked, if amyloid began accumulating again in patients brains?I love the idea of being able to stop the treatment, said Colette Johnston, the panels patient representative. But I am concerned about what happens if we're not following up, and we're not getting that information once we discontinue the dosing.Both FDA staff and panelists were also focused on a type of brain swelling and bleeding, known as ARIA, that occurred in people treated with donanemab and other drugs like it. ARIA is quite often asymptomatic and is only identified via magnetic resonance imagingBut at least two donanemab-treated participants, and possibly a third, died as a result of ARIA episodes, raising questions about the drugs safety if approved for general use.Lilly executives said that, later in the trial, they were able to better identify asymptomatic cases by having patients undergo more frequent MRIs. In these people, the company delayed additional drug infusions until brain swelling subsided to prevent it from becoming more serious.For people at high risk of ARIA, such as those with a genetic marker named APOE4, Lilly executives said they would recommend closer monitoring.Patients, caregivers and physicians testified at the hearing, almost all of whom asked the committee to recommend an approval. One, a 75-year-old man who participated in Lillys trial, said he had an infusion-related side effect that ended with an emergency room visit. Even so, he said he concluded donanemabs benefits still counterbalanced its risks and decided to remain in the study.“The community understands that donanemab is not curative, but has shown in promising clinical trials it can delay progression of disease,“ Sue Peschin, CEO of the Alliance for Aging Research, said. “This is of key importance to people living with early Alzheimer's where quality of life outcomes such as cognition, personality, and the ability to care for oneself are the ones that matter most.Estimates hold that roughly 6 million to 7 million people in the U.S. have Alzheimers. The disease is a leading cause of death, and inflicts an immense physical, mental and emotional toll on patients and their caregivers. It is also extremely expensive. Research published in the American Journal of Managed Care noted how, in 2022, the estimated healthcare costs associated with Alzheimers treatment were $321 billion.For Lilly, approval would cap off a decades-long mission to get an Alzheimers medication on the market. The company came somewhat close years ago with a similar drug called solanezumab, though clinical failures led to the therapy getting scrapped.On Wall Street, analysts expect an approval would add another blockbuster product to Lillys portfolio, which has been buoyed by the success of the companys GLP-1 drug for obesity. As of early March, the average analyst estimate had donanemab generating close to $3 billion in annual sales at its peak, according to the investment firm Jefferies.Editors note: This story has been updated with additional detail from the meeting. '

Drug Approval

15 May 2024

·firstwordpharma.com

Eisai, Biogen kick off FDA submission for subcutaneous Leqembi after initial setback

After securing the much-awaited FDA fast-track designation, Eisai and Biogen announced that they have commenced a rolling submission of the marketing application for the subcutaneous (SC) version of Leqembi (lecanemab) in the maintenance treatment of early Alzheimer's disease (AD). The agency earlier clarified that the fast-track designation for the approved intravenous (IV) Leqembi version did not extend to the new formulation, necessitating a separate regulatory filing. Originally scheduled for March, the rolling submission was delayed after the FDA requested additional three-month immunogenicity data on the SC formulation from Eisai. Based on the postponed filing date, UBS analysts at that time said a decision could come in the second half of next year. Potential gamechangerThe application is backed by open-label extension and modelled data from the Phase III Clarity AD study. The companies noted that the SC autoinjector would enable faster administration of the anti-amyloid-beta antibody at home or in medical facilities compared with the IV version. Furthermore, a weekly maintenance regimen with the SC formulation is likely to maintain effective drug levels following biweekly IV initiation. Neurologists interviewed in a FirstWord poll echoed the sentiment, with 62% of respondents deeming SC Leqembi superior to the IV version and anticipating improved access to the drug in underserved rural areas. Approval of the new formulation could be a significant win for the partners, who are currently struggling to boost the drug’s global adoption. In March, Eisai said fewer than 4000 patients had been treated with Leqembi, far below the targeted 10,000 patients by the end of 2023. Despite this, Biogen’s latest earnings report indicated a steady growth in Leqembi sales — reaching $19 million in the first quarter, nearly tripling its sales from the previous three months.

Phase 3Fast Track

13 May 2024

·www.biospace.com

Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials

Pictured: An arrow splitting toward pills and money, or pills and headstones/Taylor Tieden for BioSpace It’s been a little over a month since Amylyx Pharmaceuticals announced it would withdraw its amyotrophic lateral sclerosis drug Relyvrio from the market after it failed to meet the primary endpoints in a Phase III trial. Relyvrio received approval in 2022 after a positive Phase II study and the company had vowed to pull it if the second trial was not successful. Relyvrio isn’t the first drug to be withdrawn from the market after additional trials have failed to reaffirm earlier studies supporting the efficacy and safety of novel therapies. Conversely, some drugs stay on the market for years after confirmatory trials don’t deliver the expected results. For example, Jazz Pharmaceuticals and PharmaMar’s Zepzelca remains on the market for small cell lung cancer despite not meeting overall survival endpoints. Even for drugs that have yet to reach the market, companies can be faced with tough decisions when late-stage trials do not yield the expected results. BrainStorm Cell Therapeutics, for example, continues to develop its cell therapy NurOwn for ALS even after a Phase III trial failed to meet its primary endpoint and an FDA advisory committee voted against approval last year. Market withdrawal and pipeline decisions after late-stage failures depend on a number of factors, including the details of the study’s data. “The first thing that comes to mind is, why did the trial fail? Is it related to efficacy, safety, or both?” Nicolas Schmitz, a senior market analyst at KBI Biopharma, told BioSpace in an email. “The nature of the failure (statistical significance, side effects or patient recruitment challenges) will obviously play a crucial role in the future of the drug candidate and the company that owns it.” Not Cut and Dry In the last few years, there have been a handful of approved drugs withdrawn from the market. TG Therapeutics received accelerated approval for Ukoniq in February 2021 but voluntarily withdrew the lymphoma drug in 2022 after updated data showed a possible increased risk of death. Gilead Sciences’ Zydelig for lymphoma and small lymphocytic leukemia received accelerated approval in 2014 but was voluntarily withdrawn in 2022 after enrollment challenges hindered its confirmatory trial. And Genentech’s Tecentriq won accelerated approval in 2016 for urothelial carcinoma but failed to meet its overall survival endpoint in a Phase III trial the following year for patients with locally advanced or metastatic urothelial cancer who had been treated with platinum chemotherapy. It was withdrawn from the market in 2021 for this indication, with additional indications being pulled in 2022. Failed trials play a key role in earlier development decisions too. For example, a failed Phase III study can cause some companies to shutter entire development programs, while others will continue pushing forward with additional studies, perhaps with different trial designs or targeting different patient populations. In September 2023, when the FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 17-1 against recommending NurOwn for approval, the company decided to continue developing the therapy. “We’re heartened and encouraged by the support of the community, but it really comes back to the evidence that we have which drives us,” Co-CEO Stacy Lindborg told BioSpace. The advisory committee had been critical of the company’s manufacturing plan and questioned the greater mortality rate in the experimental group. Moreover, the primary endpoint of BrainStorm’s Phase III trial—the proportion of participants experiencing an improvement of 1.25 points per month post-treatment on the ALSFRS-R vs. placebo—did not meet statistical significance. However, this endpoint was achieved in a subset of patients. “At face value, we took the endpoints, and our first inclination was that this is a failed trial,” Lindborg said, adding that all companies have a responsibility to trial participants to understand what they have learned. “When we started seeing that the cells had done what we expected, we started to ask additional questions.” Indeed, the team saw in the trial data improvements in neurofilament light and other markers of neurodegenerative disease, Lindborg said. BrainStorm came to an agreement with the FDA on the design of a Phase IIIb trial for NurOwn in February 2024. Lindborg is optimistic that the trial will succeed, but would not comment on what action the company would take if the new endpoints are not met. Sarepta Therapeutics is also looking to move forward with a therapy that hasn’t delivered as expected in clinical trials. The FDA accepted Sarepta’s supplemental Biologics License Application (sBLA) for full approval and to expand the label of its Duchenne muscular dystrophy gene therapy Elevidys earlier this year, despite its failing a confirmatory trial in October 2023. The company expects a decision on or before June 21. Financial Factors Finances also play a role in whether companies pursue additional trials in the face of less-than-ideal results. A larger company might have more freedom to pursue further development following a failure than a small company would. Schmitz pointed to Eli Lilly’s solanezumab, which failed to meet endpoints in multiple trials before being dropped in 2023, as an example. Lilly earned more than $34 billion in revenue in 2023, with 63% of that coming from a handful of drugs. In comparison, Amylyx earned $380 million in revenue in 2023, with Relyvrio its only marketed product. If a company is “struggling with cash” with no alternative products, a failed trial “might certainly be the end of the adventure” for that company, he said. “The key tenets of every product are cycle time, cost and value,” Lindborg said. “Is there an appropriate need, such that what you’re investing can be recouped and that you’re able to continue to do research in the future?” Companies may also sell drug programs that failed in clinical trials to companies with the resources to continue research and development, Schmitz said. Lindborg added that partnerships between companies could help cost-effectiveness and efficiency by sharing capacity and headcount across organizations. Whether or not a drug is withdrawn from the market or development is halted ultimately affects whether trial participants and other patients can access that drug. A study examining cancer drugs that failed clinical trials after receiving accelerated approval found that multiple drugs were still recommended by the National Comprehensive Cancer Network even after negative results were available. Amylyx will continue to make Relyvrio available for free to patients who believe the drug is helping them, a decision that was commended by The ALS Association, according to The Washington Post. “We try to boil every question down to, what’s best for people with the disease, what’s best for the families, what’s best for the community,” Amylyx Co-CEO Justin Klee told BioSpace last month. “We ran a large, randomized control trial. It was a very well-done trial, and the benefit was uncertain.” Nadia Bey is a freelance reporter in North Carolina. Her work and contact information can be found at nadiabey.com.

Phase 3Phase 2Accelerated Approval

100 Deals associated with Solanezumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10058	Solanezumab	-	DB11756

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	US	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	DE	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	GB	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	BR	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	TW	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	RU	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	AR	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	IT	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	PL	Eli Lilly & Co.	01 May 2009
Alzheimer Disease	Preclinical	KR	Eli Lilly & Co.	01 May 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed	Not Applicable	Alzheimer Disease	-	Solanezumab	nuhnchcxdb(fhfyakrkuk) = tixprypqeb ppbayyagnz (nsghpzzwth, 0.43)	-	29 Apr 2024
NCT02760602 (ExpeditionPRO, CTgov)	Phase 3	Alzheimer Disease	26	Solanezumab (Solanezumab)	yqtqljcpgf(remwanswhy) = ldpazonlmh ngsvavsjxy (kokaahnitc, nlkpexyyyw - meeijizqfe) View more	-	24 Jul 2018
				Placebo (Placebo)	yqtqljcpgf(remwanswhy) = ilmpgcbvey ngsvavsjxy (kokaahnitc, ukcuwogkeq - fbgtnynaon) View more
NCT01127633 (EXPEDITION EXT, CTgov)	Phase 3	Alzheimer Disease	1,457	Placebo (Placebo)	smpgklpmww(dtiqcdwobk) = gyhkiqxlxq fcborwornp (ucxnzsfnid, axuqschyfn - rwkbltfcef) View more	-	03 May 2018
				Solanezumab (Solanezumab)	smpgklpmww(dtiqcdwobk) = sbtfuvxhkk fcborwornp (ucxnzsfnid, bibynotgba - rphekclzqk) View more
NCT01900665 (EXPEDITION3 \| EXPEDITION 3, CTgov)	Phase 3	Alzheimer Disease	2,129	Solanezumab (Solanezumab)	ghjilrmahr(odgblgqqxd) = dxaiedvxuu vfnrjvtleq (ypixxuplli, pgyloygkos - lznbmjrpwp) View more	-	14 Mar 2018
				Placebo (Placebo)	ghjilrmahr(odgblgqqxd) = rwsxjqdibr vfnrjvtleq (ypixxuplli, faejkqkskc - jojfzvdxmy) View more
NCT01900665 (EXPEDITION3, Pubmed \| Br Dent J) Manual	Phase 3	Alzheimer Disease \| Dementia	2,129	Solanezumab	(hjwbboftvw) = pmovchgujh tctvuutkxa (nlfyqaxlox ) View more	Negative	25 Jan 2018
				Placebo	(hjwbboftvw) = bamdpemrib tctvuutkxa (nlfyqaxlox ) View more
NCT01900665 (EXPEDITION3, AAIC2017)	Phase 3	Alzheimer Disease	2,129	Solanezumab	dpuhdxmpgn(mjdjcfklym) = bvuhkqfgiu ityxbrkmnc (ehbxwuvegl ) View more	-	01 Jul 2017
NCT00904683 \| NCT01900665 \| NCT00905372 (EXPEDITION3, AAIC2017)	Not Applicable	Alzheimer Disease	-	Solanezumab	(vyserydjsn) = ftobwuoqoi qqweywtwle (cilssfilkh ) View more	-	01 Jul 2017
EXPEDITION and EXPEDITION2 (AAIC2014)	Not Applicable	Alzheimer Disease	-	Solanezumab	lwvbyqpprt(tcgoeeilwf) = asgdpkatgv boweonqgqe (ckwkxowdxm ) View more	-	01 Jul 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis